Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective cut by investment analysts at Truist Financial from $11.00 to $8.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other equities research analysts also recently issued reports on the company. BMO Capital Markets restated an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. Wedbush restated an “outperform” rating and issued a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday. Bank of America cut their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Piper Sandler cut their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, Royal Bank Of Canada lowered Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $14.00 to $4.00 in a research report on Monday, October 26th. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.70.

Perspective Therapeutics Stock Down 1.5%

Perspective Therapeutics stock traded down $0.01 during trading on Tuesday, reaching $0.84. 1,533,429 shares of the company’s stock were exchanged, compared to its average volume of 2,348,584. Perspective Therapeutics has a 52-week low of $0.78 and a 52-week high of $6.16. The company’s 50-day moving average is $2.29 and its two-hundred day moving average is $3.48.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Equities research analysts forecast that Perspective Therapeutics will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its position in Perspective Therapeutics by 391.6% during the first quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company’s stock valued at $1,877,000 after buying an additional 358,540 shares during the period. Avidity Partners Management LP increased its stake in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after purchasing an additional 2,839,266 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Perspective Therapeutics during the 1st quarter worth $1,581,000. Yu Fan bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at $4,401,000. Finally, Commodore Capital LP bought a new position in Perspective Therapeutics during the first quarter valued at about $26,424,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.